Cargando…

Monkeypox

Monkeypox is a zoonotic illness caused by the monkeypox virus, an Orthopoxvirus in the same genus as the variola, vaccinia, and cowpox viruses. Since the detection of the first human case in the Democratic Republic of the Congo in 1970, the disease has caused sporadic infections and outbreaks, mainl...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitjà, Oriol, Ogoina, Dimie, Titanji, Boghuma K, Galvan, Cristina, Muyembe, Jean-Jacques, Marks, Michael, Orkin, Chloe M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671644/
https://www.ncbi.nlm.nih.gov/pubmed/36403582
http://dx.doi.org/10.1016/S0140-6736(22)02075-X
_version_ 1784832595273449472
author Mitjà, Oriol
Ogoina, Dimie
Titanji, Boghuma K
Galvan, Cristina
Muyembe, Jean-Jacques
Marks, Michael
Orkin, Chloe M
author_facet Mitjà, Oriol
Ogoina, Dimie
Titanji, Boghuma K
Galvan, Cristina
Muyembe, Jean-Jacques
Marks, Michael
Orkin, Chloe M
author_sort Mitjà, Oriol
collection PubMed
description Monkeypox is a zoonotic illness caused by the monkeypox virus, an Orthopoxvirus in the same genus as the variola, vaccinia, and cowpox viruses. Since the detection of the first human case in the Democratic Republic of the Congo in 1970, the disease has caused sporadic infections and outbreaks, mainly restricted to some countries in west and central Africa. In July, 2022, WHO declared monkeypox a Public Health Emergency of International Concern, on account of the unprecedented global spread of the disease outside previously endemic countries in Africa and the need for global solidarity to address this previously neglected disease. The 2022 outbreak has been primarily associated with close intimate contact (including sexual activity) and most cases have been diagnosed among men who have sex with men, who often present with novel epidemiological and clinical characteristics. In the 2022 outbreak, the incubation period ranges from 7 days to 10 days and most patients present with a systemic illness that includes fever and myalgia and a characteristic rash, with papules that evolve to vesicles, pustules, and crusts in the genital, anal, or oral regions and often involve the mucosa. Complications that require medical treatment (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of patients and include rectal pain, odynophagia, penile oedema, and skin and anorectal abscesses. Most patients have a self-limited illness; between 1% and 13% require hospital admission (for treatment or isolation), and the case-fatality rate is less than 0·1%. A diagnosis can be made through the presence of Orthopoxvirus DNA in PCRs from lesion swabs or body fluids. Patients with severe manifestations and people at risk of severe disease (eg, immunosuppressed people) could benefit from antiviral treatment (eg, tecovirimat). The current strategy for post-exposure prophylaxis or pre-exposure prophylaxis for people at high risk is vaccination with the non-replicating modified vaccinia Ankara. Antiviral treatment and vaccines are not yet available in endemic countries in Africa.
format Online
Article
Text
id pubmed-9671644
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-96716442022-11-21 Monkeypox Mitjà, Oriol Ogoina, Dimie Titanji, Boghuma K Galvan, Cristina Muyembe, Jean-Jacques Marks, Michael Orkin, Chloe M Lancet Seminar Monkeypox is a zoonotic illness caused by the monkeypox virus, an Orthopoxvirus in the same genus as the variola, vaccinia, and cowpox viruses. Since the detection of the first human case in the Democratic Republic of the Congo in 1970, the disease has caused sporadic infections and outbreaks, mainly restricted to some countries in west and central Africa. In July, 2022, WHO declared monkeypox a Public Health Emergency of International Concern, on account of the unprecedented global spread of the disease outside previously endemic countries in Africa and the need for global solidarity to address this previously neglected disease. The 2022 outbreak has been primarily associated with close intimate contact (including sexual activity) and most cases have been diagnosed among men who have sex with men, who often present with novel epidemiological and clinical characteristics. In the 2022 outbreak, the incubation period ranges from 7 days to 10 days and most patients present with a systemic illness that includes fever and myalgia and a characteristic rash, with papules that evolve to vesicles, pustules, and crusts in the genital, anal, or oral regions and often involve the mucosa. Complications that require medical treatment (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of patients and include rectal pain, odynophagia, penile oedema, and skin and anorectal abscesses. Most patients have a self-limited illness; between 1% and 13% require hospital admission (for treatment or isolation), and the case-fatality rate is less than 0·1%. A diagnosis can be made through the presence of Orthopoxvirus DNA in PCRs from lesion swabs or body fluids. Patients with severe manifestations and people at risk of severe disease (eg, immunosuppressed people) could benefit from antiviral treatment (eg, tecovirimat). The current strategy for post-exposure prophylaxis or pre-exposure prophylaxis for people at high risk is vaccination with the non-replicating modified vaccinia Ankara. Antiviral treatment and vaccines are not yet available in endemic countries in Africa. Elsevier Ltd. 2023 2022-11-17 /pmc/articles/PMC9671644/ /pubmed/36403582 http://dx.doi.org/10.1016/S0140-6736(22)02075-X Text en © 2022 Elsevier Ltd. All rights reserved. Elsevier has created a Monkeypox Information Center (https://www.elsevier.com/connect/monkeypox-information-center) in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active.
spellingShingle Seminar
Mitjà, Oriol
Ogoina, Dimie
Titanji, Boghuma K
Galvan, Cristina
Muyembe, Jean-Jacques
Marks, Michael
Orkin, Chloe M
Monkeypox
title Monkeypox
title_full Monkeypox
title_fullStr Monkeypox
title_full_unstemmed Monkeypox
title_short Monkeypox
title_sort monkeypox
topic Seminar
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671644/
https://www.ncbi.nlm.nih.gov/pubmed/36403582
http://dx.doi.org/10.1016/S0140-6736(22)02075-X
work_keys_str_mv AT mitjaoriol monkeypox
AT ogoinadimie monkeypox
AT titanjiboghumak monkeypox
AT galvancristina monkeypox
AT muyembejeanjacques monkeypox
AT marksmichael monkeypox
AT orkinchloem monkeypox